Literature DB >> 18700309

[Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59].

Marcin Dominiak1.   

Abstract

Entities:  

Year:  2008        PMID： 18700309

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN： 0022-9032            Impact factor:   3.108


× No keyword cloud information.
  8 in total

1.  [Antihypertensive drug therapy : Where do we stand?].

Authors:  M Middeke
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

2.  Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society.

Authors:  Eiichi Araki; Atsushi Tanaka; Nobuya Inagaki; Hiroshi Ito; Kohjiro Ueki; Toyoaki Murohara; Kenjiro Imai; Masataka Sata; Takehiro Sugiyama; Hideki Ishii; Shunsuke Yamane; Takashi Kadowaki; Issei Komuro; Koichi Node
Journal:  Diabetol Int       Date:  2020-11-30

Review 3.  Current therapeutic approaches to cardio-protection in hypertension.

Authors:  David Parra; Augustus Hough
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

4.  Polypharmacy, potentially serious clinically relevant drug-drug interactions, and inappropriate medicines in elderly people with type 2 diabetes and their impact on quality of life.

Authors:  Labib Al-Musawe; Carla Torre; Jose Pedro Guerreiro; Antonio Teixeira Rodrigues; Joao Filipe Raposo; Helder Mota-Filipe; Ana Paula Martins
Journal:  Pharmacol Res Perspect       Date:  2020-08

5.  Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.

Authors:  Wang-Qing Chen; Yan Shu; Qing Li; Lin-Yong Xu; Mary W Roederer; Lan Fan; Lan-Xiang Wu; Fa-Zhong He; Jian-Quan Luo; Zhi-Rong Tan; Yi-Jing He; Hong-Hao Zhou; Xiang Chen; Wei Zhang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 6.  Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.

Authors:  Francesca Viazzi; Giovanna Leoncini; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-10-04

Review 7.  Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.

Authors:  Stefano Omboni; Massimo Volpe
Journal:  Adv Ther       Date:  2018-12-27       Impact factor: 3.845

8.  An empirical study on the index system of rational drug use in children with primary nephrotic syndrome: A cross-sectional study.

Authors:  Mao Lin; Liang Huang; Linan Zeng; Lingli Zhang
Journal:  Medicine (Baltimore)       Date:  2020-08-07       Impact factor: 1.817
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.